A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
| Autor: | Chun Hang Tang, Beulah Ji, Ana Malvar, Y K Onno Teng, Brad H. Rovin, Jennifer A Gilbride, Gabriel Contreras, Richard Furie, David M. Roth, Xueqing Yu, Damon Bass, Yulia Green, Tania Gonzalez-Rivera |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Cyclophosphamide Population Lupus nephritis Renal function Azathioprine Antibodies Monoclonal Humanized Kidney Gastroenterology chemistry.chemical_compound systemic lupus erythematosus Internal medicine medicine Humans Lupus Erythematosus Systemic kidney function skin and connective tissue diseases education lupus nephritis Creatinine education.field_of_study business.industry Standard treatment Symptom Flare Up medicine.disease Belimumab Treatment Outcome chemistry Nephrology belimumab business Immunosuppressive Agents medicine.drug |
| Zdroj: | Kidney International, 101(2), 403-413. ELSEVIER SCIENCE INC |
| ISSN: | 0085-2538 |
| Popis: | We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients with lupus nephritis were randomized to receive intravenous belimumab 10 mg/kg or placebo with standard therapy (cyclophosphamide/azathioprine or mycophenolate mofetil). Add-on belimumab was found to be most effective in improving the primary efficacy kidney response and complete kidney response in patients with proliferative lupus nephritis and a baseline urine protein/creatinine ratio under 3 g/g. However, there was no observed improvement in the kidney response with belimumab treatment in patients with lupus nephritis and sub-epithelial deposits or with a baseline protein/creatinine ratio of 3 g/g or more. Belimumab significantly reduced the risk of kidney-related events or death and lupus nephritis flare in the overall population. Belimumab reduced the risk of a sustained 30% or 40% decline in estimated glomerular filtration rate (eGFR) versus standard treatment alone and attenuated the annual rate of eGFR decline in patients who remained on-study. Thus, our data suggest that the addition of belimumab to standard therapy could attenuate the risk of lupus nephritis flare and eGFR decline in a broad spectrum of patients with lupus nephritis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|